Company Profile

IcellKealex Therapeutics LLC (AKA:IKT~AnoVac Inc~Icell Kealex Therapeutics LLC)
Profile last edited on: 7/18/2022

Novel oncolytic virus platform: T-cell engager armed vaccinia virus (TEA-VV).
Year Founded
2915
First SBIR Year
2020
Latest SBIR Award
2020
Program Status
Active

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

2450 Holcombe Boulevard Suite J206
Houston, TX 77021
   (281) 987-4294
   N/A
   www.icellkealex.com
Multiple Locations:   
Congressional District:   18
County:   Harris

Public Profile

Founded by scientists working at Baylor College of Medicine and selected to join Houston TX JLABS@TMC in Feb 2016, Icell Kealex Therapeutics (IKT)- also dba AnoVac Inc - is a pre-clinical/IND stage biotechnology start-up pioneering development of novel proprietary oncolytic virus based cancer immunotherapeutics. The firm's principals are developing an novel Oncolytic Vaccinia Virus variant suitable for systemic delivery. The effectiveness of oncolytic viruses is limited by the strong immune response induced by the virus, such as neutralizing antibodies and complement. To ddress that problem, principals of the firm have developed a Neutralization Escape Variant of Oncolytic Vaccinia Virus (VVNEV) platform technology. The objective is to generate a next-generation oncolytic VV with the ability of escaping the hostÂ’s neutralization antibody response, thus allowing a systemic delivery of the recombinant virus to the tumor cells.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
---
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount Project Title
2020 2 NIH $445,916
BCMA-Targeted Oncolytic Virus for Multiple Myeloma

Key People / Management

  Xiao-Tong Song -- Founding Partner abd CEO

  Wei Zhu --

SBIR firms in the news

There are no news available.